Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.

Domenica M Rubino Jakob Bue BjornerNaveen RathorArya M SharmaLisa von Huth SmithSean Wharton Thomas A WaddenNiels ZeuthenRonette L Kolotkin

Published in: Diabetes, obesity & metabolism (2024)

Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.

Keyphrases

physical activity
weight loss
patient reported
mental health
weight gain
metabolic syndrome
body mass index
insulin resistance
type diabetes
clinical trial
randomized controlled trial
adipose tissue
high fat diet induced
body weight
open label
placebo controlled